IDT Australia Limited · ASX:IDT

IDT Australia — H1 FY2021 Earnings Presentation

9 slides from IDT Australia's earnings presentation, Feb 23, 2021

  1. Slide 1: IDT Australia Limited 2021 Interim Results and Investor Update

    IDT AUSTRALIA LIMITED 2021 INTERIM RESULTS AND INVESTOR UPDATE FOR THE SIX MONTHS ENDED 31 DECEMBER 2020 23 February 2021

  2. Slide 2: Interim Results H1 FY21 Highlights

    2 Interim Results H1 FY21 Highlights COVID-19 Treatments and Vaccines – IDT Putting Forward Its Capabilities IDT’s business has continued to operate throughout the pandemic. During the reporting period the Company completed activities assisting the Federal Government in its initial COVID-19 response

  3. Slide 3: Key Financial Highlights

    Key Financial Highlights Strong cash balance of $7.32 million Half Year ended 31 December (‘$000) 2021 2020 Variance Year-on-year Revenue decrease of 19% to $5.80 million (Half Results from operations including adjustments* Year FY20 includes $0.9 million previously capitalised milestone) Positive E

  4. Slide 4: COVID-19 Vaccines and Treatments

    2 COVID-19 Vaccines and Treatments Putting forward IDT’s COVID-19 vaccine and treatment manufacturing capabilities • In August 2020 the Australian Government tendered a Request For Information (RFI) seeking information regarding COVID-19 vaccine and treatment manufacture and supply, in particular ma

  5. Slide 5: IDT's Sovereign Manufacturing Initiative

    2 IDT’s Sovereign Manufacturing Initiative Re-shoring the manufacture of Australia’s essential medicines • The initial phase of the COVID-19 crisis exposed the fragility of Australia’s pharmaceutical supply chain. As Australia’s last remaining small molecule API manufacturer and one of a handful of

  6. Slide 6: IDT's Medicinal Cannabis Manufacturing Plan

    2 IDT’s Medicinal Cannabis Manufacturing Plan Good progress on IDT’s stated objective of developing cGMP medicinal cannabis APIs and finished dosage forms • IDT’s extraction and purification facilities are now producing a range of cGMP medicinal cannabis resins and further refined Active Pharmaceuti

  7. Slide 7: Year In Review – Half Year check-in

    Year In Review – Half Year check-in [Slide presented at IDT’s 2020 Annual General Meeting] including COVID-19 Treatment and Vaccine Manufacture COVID-19 Treatment and Vaccine Manufacture – TGA and FDA accredited Advance IDT’s Sovereign site at the ready Manufacturing Initiative    Pushing Towards

  8. Slide 8: Board of Directors and Executive Team

    IDT Australia Limited Board of Directors Executive Team Mr Alan Fisher Chair Dr David Sparling CEO Finance specialist with key experience More than 20 years of pharma anddiagnostic experience in in business restructuring andcompany CEO,Director andcorporate/business development roles. turnarounds. (

  9. Slide 9: Disclaimer

    DISCLAIMER This presentation contains forward looking statements which involve known and unknown risks. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors which could cause actualresults and devel

IDT Australia — H1 FY2021 Earnings Presentation on 6ix